{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:26:09Z","timestamp":1783977969201,"version":"3.55.0"},"reference-count":141,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Radiotherapy is a mainstay in glioblastoma therapy as it not only directly targets tumor cells but also depletes the tumor microvasculature. The resulting intra-tumoral hypoxia initiates a chain of events that ultimately leads to re-vascularization, immunosuppression and, ultimately, tumor-regrowth. The key component of this cascade is overexpression of the CXC-motive chemokine ligand 12 (CXCL12), formerly known as stromal-cell derived factor 1 (SDF-1). We here review the role of CXCL12 in recruitment of pro-vasculogenic and immunosuppressive cells and give an overview on future and current drugs that target this axis.<\/jats:p>","DOI":"10.3390\/cancers11030272","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T11:00:44Z","timestamp":1551178844000},"page":"272","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Targeting the Post-Irradiation Tumor Microenvironment in Glioblastoma via Inhibition of CXCL12"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5243-4781","authenticated-orcid":false,"given":"Frank A.","family":"Giordano","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Link","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Glas","sequence":"additional","affiliation":[{"name":"Division of Clinical Neurooncology, Department of Neurology and West German Cancer Center (WTZ), University Hospital Essen and German Cancer Consortium, Partner Site University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Herrlinger","sequence":"additional","affiliation":[{"name":"Division of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, 53105 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Wenz","sequence":"additional","affiliation":[{"name":"CEO, University Medical Center Freiburg, 79110 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Umansky","sequence":"additional","affiliation":[{"name":"Skin Cancer Unit, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"},{"name":"Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Martin","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Neurology, Stanford University School of Medicine, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6554-5907","authenticated-orcid":false,"given":"Carsten","family":"Herskind","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00005-012-0203-0","article-title":"Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies","volume":"61","author":"Agnihotri","year":"2013","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/neuonc\/not151","article-title":"CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006\u20132010","volume":"15","author":"Ostrom","year":"2013","journal-title":"Neuro-Oncology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0140-6736(03)12328-8","article-title":"Primary brain tumours in adults","volume":"361","author":"Behin","year":"2003","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.hoc.2006.09.012","article-title":"Cognitive functions in brain tumor patients","volume":"20","author":"Correa","year":"2006","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1093\/annonc\/mdt388","article-title":"Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy","volume":"24","author":"Kreth","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_6","first-page":"669","article-title":"An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825","volume":"19","author":"Gittleman","year":"2017","journal-title":"Neuro-Oncology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","article-title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial","volume":"13","author":"Malmstrom","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","article-title":"Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised, phase 3 trial","volume":"13","author":"Wick","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1200\/JCO.2016.70.7562","article-title":"Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline","volume":"35","author":"Sulman","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs. Maintenance Temozolomide Alone on Survival in Patients with Glioblastoma: A Randomized Clinical Trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"iv17","DOI":"10.1093\/neuonc\/nos161","article-title":"Neurocognitive functioning in adult WHO grade II gliomas: Impact of old and new treatment modalities","volume":"14","author":"Klein","year":"2012","journal-title":"Neuro-Oncology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3346\/jkms.2014.29.7.980","article-title":"Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea","volume":"29","author":"Bae","year":"2014","journal-title":"J. Korean Med. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"831090","DOI":"10.1155\/2012\/831090","article-title":"Impact of temozolomide on immune response during malignant glioma chemotherapy","volume":"2012","author":"Sengupta","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11060-009-9993-2","article-title":"Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: Initial findings","volume":"97","author":"Hilverda","year":"2010","journal-title":"J. Neurooncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa065901","article-title":"Radiotherapy for glioblastoma in the elderly","volume":"356","author":"Chinot","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"vi13","DOI":"10.1093\/neuonc\/nox168.049","article-title":"ACTR-58. Phase III trial of CCNU\/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT-methylated glioblastoma patients: THE CeTeg\/NOA-09 trial","volume":"19","author":"Herrlinger","year":"2017","journal-title":"Neuro-Oncology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/glia.21137","article-title":"Signal transduction inhibitors and antiangiogenic therapies for malignant glioma","volume":"59","author":"Mellinghoff","year":"2011","journal-title":"Glia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11060-013-1232-1","article-title":"Mitogenic signalling in the absence of epidermal growth factor receptor activation in a human glioblastoma cell line","volume":"115","author":"Wang","year":"2013","journal-title":"J. Neurooncol."},{"key":"ref_21","first-page":"200","article-title":"Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling","volume":"62","author":"Chakravarti","year":"2002","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and Bevacizumab in Progressive Glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1084\/jem.102.2.213","article-title":"Allergic neuritis: An experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvants","volume":"102","author":"Waksman","year":"1955","journal-title":"J. Exp. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature14432","article-title":"Structural and functional features of central nervous system lymphatic vessels","volume":"523","author":"Louveau","year":"2015","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","article-title":"Current state of immunotherapy for glioblastoma","volume":"15","author":"Lim","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11060-015-1810-5","article-title":"Concepts of immunotherapy for glioma","volume":"123","author":"Patel","year":"2015","journal-title":"J. Neurooncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s004010100448","article-title":"Cytokine and cytokine receptor mRNA expression in human glioblastomas: Evidence of Th1, Th2 and Th3 cytokine dysregulation","volume":"103","author":"Hao","year":"2002","journal-title":"Acta Neuropathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature19364","article-title":"Ionic immune suppression within the tumour microenvironment limits T cell effector function","volume":"537","author":"Eil","year":"2016","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13059-016-1028-7","article-title":"Comprehensive analyses of tumor immunity: Implications for cancer immunotherapy","volume":"17","author":"Li","year":"2016","journal-title":"Genome Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/bs.acr.2015.04.002","article-title":"Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment","volume":"128","author":"Parker","year":"2015","journal-title":"Adv. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","article-title":"Myeloid-derived suppressor cells coming of age","volume":"19","author":"Veglia","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3389\/fimmu.2015.00523","article-title":"Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate","volume":"6","author":"Meirow","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00262-011-1161-9","article-title":"Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients","volume":"61","author":"Filipazzi","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3389\/fimmu.2018.00398","article-title":"Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression","volume":"9","author":"Fleming","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Condamine, T., Dominguez, G.A., Youn, J.I., Kossenkov, A.V., Mony, S., Alicea-Torres, K., Tcyganov, E., Hashimoto, A., Nefedova, Y., and Lin, C. (2016). Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci. Immunol., 1.","DOI":"10.1126\/sciimmunol.aaf8943"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.semcancer.2012.02.008","article-title":"New insights into chronic inflammation-induced immunosuppression","volume":"22","author":"Kanterman","year":"2012","journal-title":"Semin. Cancer Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.it.2010.10.002","article-title":"Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function","volume":"32","author":"Condamine","year":"2011","journal-title":"Trends Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: A leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.immuni.2013.02.007","article-title":"Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation","volume":"38","author":"Kanterman","year":"2013","journal-title":"Immunity"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1158\/0008-5472.CAN-11-1792","article-title":"Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment","volume":"72","author":"Lesokhin","year":"2012","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1172\/JCI80006","article-title":"Tumor-induced myeloid deviation: When myeloid-derived suppressor cells meet tumor-associated macrophages","volume":"125","author":"Ugel","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1182\/blood-2008-01-136895","article-title":"Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice","volume":"111","author":"Sawanobori","year":"2008","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1471-4906(00)01812-3","article-title":"RANTES: A versatile and controversial chemokine","volume":"22","author":"Appay","year":"2001","journal-title":"Trends Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/NEN.0000000000000183","article-title":"Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue","volume":"74","author":"Gielen","year":"2015","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/neuonc\/nor042","article-title":"Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma","volume":"13","author":"Raychaudhuri","year":"2011","journal-title":"Neuro-Oncology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/neuonc\/nov280","article-title":"CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients","volume":"18","author":"Dubinski","year":"2016","journal-title":"Neuro-Oncology"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Alban, T.J., Alvarado, A.G., Sorensen, M.D., Bayik, D., Volovetz, J., Serbinowski, E., Mulkearns-Hubert, E.E., Sinyuk, M., Hale, J.S., and Onzi, G.R. (2018). Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight, 3.","DOI":"10.1172\/jci.insight.122264"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.3892\/ol.2016.4952","article-title":"Glioblastoma multiforme: Effect of hypoxia and hypoxia inducible factors on therapeutic approaches","volume":"12","author":"Huang","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Monteiro, A.R., Hill, R., Pilkington, G.J., and Madureira, P.A. (2017). The Role of Hypoxia in Glioblastoma Invasion. Cells, 6.","DOI":"10.3390\/cells6040045"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00005072-200606000-00001","article-title":"\u2018Pseudopalisading\u2019 necrosis in glioblastoma: A familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis","volume":"65","author":"Rong","year":"2006","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.ijrobp.2014.03.043","article-title":"Is indirect cell death involved in response of tumors to stereotactic radiosurgery and stereotactic body radiation therapy?","volume":"89","author":"Song","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1172\/JCI42345","article-title":"Resisting arrest: A switch from angiogenesis to vasculogenesis in recurrent malignant gliomas","volume":"120","author":"Greenfield","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/carcin\/bgn066","article-title":"Hypoxia-inducible factor (HIF)-1 alpha directly enhances the transcriptional activity of stem cell factor (SCF) in response to hypoxia and epidermal growth factor (EGF)","volume":"29","author":"Han","year":"2008","journal-title":"Carcinogenesis"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1161\/01.RES.0000102937.50486.1B","article-title":"Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1","volume":"93","author":"Kelly","year":"2003","journal-title":"Circ. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1227\/01.NEU.0000290905.53685.A2","article-title":"Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival","volume":"61","author":"Bian","year":"2007","journal-title":"Neurosurgery"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11060-004-7327-y","article-title":"CXCL12 expression is predictive of a shorter time to tumor progression in low-grade glioma: A single-institution study in 50 patients","volume":"74","author":"Salmaggi","year":"2005","journal-title":"J. Neurooncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.molimm.2012.10.037","article-title":"HMGB1 and leukocyte migration during trauma and sterile inflammation","volume":"55","author":"Venereau","year":"2013","journal-title":"Mol. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3389\/fonc.2017.00147","article-title":"Immunotherapy Combined with Large Fractions of Radiotherapy: Stereotactic Radiosurgery for Brain Metastases-Implications for Intraoperative Radiotherapy after Resection","volume":"7","author":"Herskind","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.4049\/jimmunol.1102454","article-title":"The IKKalpha-dependent NF-kappaB p52\/RelB noncanonical pathway is essential to sustain a CXCL12 autocrine loop in cells migrating in response to HMGB1","volume":"188","author":"Kew","year":"2012","journal-title":"J. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1084\/jem.20111739","article-title":"HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4","volume":"209","author":"Schiraldi","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.3389\/fimmu.2018.02185","article-title":"Chemokine Heterocomplexes and Cancer: A Novel Chapter to Be Written in Tumor Immunity","volume":"9","author":"Cecchinato","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.3389\/fimmu.2018.02159","article-title":"The Role of CXC Chemokine Receptors 1\u20134 on Immune Cells in the Tumor Microenvironment","volume":"9","author":"Susek","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4049\/jimmunol.1101029","article-title":"Regulation of immune responses by prostaglandin E2","volume":"188","author":"Kalinski","year":"2012","journal-title":"J. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/onc.2016.273","article-title":"Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells","volume":"36","author":"Deng","year":"2017","journal-title":"Oncogene"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"39541","DOI":"10.1038\/srep39541","article-title":"Estrogen-induced SDF-1alpha production promotes the progression of ER-negative breast cancer via the accumulation of MDSCs in the tumor microenvironment","volume":"6","author":"Ouyang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1158\/1538-7445.AM2018-1736","article-title":"Abstract 1736: The combination of CXCR4 and checkpoint receptor inhibition improves survival in an orthotopic murine glioma model","volume":"78","author":"Wu","year":"2018","journal-title":"Cancer Res."},{"key":"ref_71","first-page":"102","article-title":"Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma","volume":"6","author":"Rempel","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10072-005-0465-y","article-title":"A multicentre prospective collection of newly diagnosed glioblastoma patients in Lombardia, Italy","volume":"26","author":"Salmaggi","year":"2005","journal-title":"Neurol. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2353\/ajpath.2008.071197","article-title":"Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha\/CXCR4 expression in glioblastomas: One plausible explanation of Scherer\u2019s structures","volume":"173","author":"Zagzag","year":"2008","journal-title":"Am. J. Pathol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.it.2007.05.007","article-title":"The SDF-1-CXCR4 signaling pathway: A molecular hub modulating neo-angiogenesis","volume":"28","author":"Petit","year":"2007","journal-title":"Trends Immunol."},{"key":"ref_75","first-page":"144","article-title":"CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment","volume":"8","author":"Wurth","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Wang, S.C., Yu, C.F., Hong, J.H., Tsai, C.S., and Chiang, C.S. (2013). Radiation therapy-induced tumor invasiveness is associated with SDF-1-regulated macrophage mobilization and vasculogenesis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0069182"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1158\/1078-0432.CCR-16-3122","article-title":"The Promise of Targeting Macrophages in Cancer Therapy","volume":"23","author":"Brown","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1172\/JCI40283","article-title":"Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice","volume":"120","author":"Kioi","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/bjc.2011.169","article-title":"Targeting SDF-1\/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas","volume":"104","author":"Tseng","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"20130686","DOI":"10.1259\/bjr.20130686","article-title":"Vasculogenesis: A crucial player in the resistance of solid tumours to radiotherapy","volume":"87","author":"Brown","year":"2014","journal-title":"Br. J. Radiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood-2013-03-493924","article-title":"The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization","volume":"123","author":"Hoellenriegel","year":"2014","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.2353\/ajpath.2006.050400","article-title":"Osteopontin expression in intratumoral astrocytes marks tumor progression in gliomas induced by prenatal exposure to N-ethyl-N-nitrosourea","volume":"168","author":"Jang","year":"2006","journal-title":"Am. J. Pathol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/neuonc\/not149","article-title":"Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats","volume":"16","author":"Liu","year":"2014","journal-title":"Neuro-Oncology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neo.2016.11.010","article-title":"SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI","volume":"19","author":"Deng","year":"2017","journal-title":"Neoplasia"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/bjc.2013.830","article-title":"Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats","volume":"110","author":"Walters","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2010.34.1636","article-title":"Phase II study of aflibercept in recurrent malignant glioma: A North American Brain Tumor Consortium study","volume":"29","author":"Lamborn","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/fncel.2014.00065","article-title":"CXCL12 chemokine and its receptors as major players in the interactions between immune and nervous systems","volume":"8","author":"Guyon","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.devcel.2015.03.018","article-title":"CXCL12 Signaling Is Essential for Maturation of the Ventricular Coronary Endothelial Plexus and Establishment of Functional Coronary Circulation","volume":"33","author":"Cavallero","year":"2015","journal-title":"Dev. Cell"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.devcel.2015.03.026","article-title":"The CXCL12\/CXCR4 Axis Plays a Critical Role in Coronary Artery Development","volume":"33","author":"Ivins","year":"2015","journal-title":"Dev. Cell"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.devcel.2013.01.009","article-title":"Peripheral nerve-derived CXCL12 and VEGF-A regulate the patterning of arterial vessel branching in developing limb skin","volume":"24","author":"Li","year":"2013","journal-title":"Dev. Cell"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"9448","DOI":"10.1073\/pnas.95.16.9448","article-title":"Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice","volume":"95","author":"Ma","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/382635a0","article-title":"Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF\/SDF-1","volume":"382","author":"Nagasawa","year":"1996","journal-title":"Nature"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1681\/ASN.2008060640","article-title":"The CXCL12 (SDF-1)\/CXCR4 axis is essential for the development of renal vasculature","volume":"20","author":"Takabatake","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/cmi.2017.107","article-title":"The unique structural and functional features of CXCL12","volume":"15","author":"Janssens","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3389\/fimmu.2015.00429","article-title":"Diversity and Inter-Connections in the CXCR4 Chemokine Receptor\/Ligand Family: Molecular Perspectives","volume":"6","author":"Pawig","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1189\/jlb.3MR0915-431RR","article-title":"Atypical chemokine receptors in cancer: Friends or foes?","volume":"99","author":"Massara","year":"2016","journal-title":"J. Leukoc. Biol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/glia.22271","article-title":"The presumed atypical chemokine receptor CXCR7 signals through G(i\/o) proteins in primary rodent astrocytes and human glioma cells","volume":"60","author":"Odemis","year":"2012","journal-title":"Glia"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev.biochem.72.121801.161747","article-title":"Regulation of protein function by glycosaminoglycans\u2014As exemplified by chemokines","volume":"74","author":"Handel","year":"2005","journal-title":"Annu. Rev. Biochem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1158\/1078-0432.CCR-13-0582","article-title":"The disparate twins: A comparative study of CXCR4 and CXCR7 in SDF-1alpha-induced gene expression, invasion and chemosensitivity of colon cancer","volume":"20","author":"Heckmann","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmed.2006.12.003","article-title":"Niche-to-niche migration of bone-marrow-derived cells","volume":"13","author":"Kaplan","year":"2007","journal-title":"Trends Mol. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.semcancer.2008.11.001","article-title":"The roles of chemokine CXCL12 in embryonic and brain tumor angiogenesis","volume":"19","author":"Li","year":"2009","journal-title":"Semin. Cancer Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/2001-1326-1-30","article-title":"Perivascular mesenchymal stem cells in the adult human brain: A future target for neuroregeneration?","volume":"1","author":"Ozen","year":"2012","journal-title":"Clin. Transl. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.bbagen.2012.10.008","article-title":"The cancer stem cell niche(s): The crosstalk between glioma stem cells and their microenvironment","volume":"1830","author":"Filatova","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1369\/0022155417752676","article-title":"Glioma Stem Cell Niches in Human Glioblastoma Are Periarteriolar","volume":"66","author":"Hira","year":"2018","journal-title":"J. Histochem. Cytochem."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.canlet.2008.09.034","article-title":"CXCR4 mediates the proliferation of glioblastoma progenitor cells","volume":"274","author":"Ehtesham","year":"2009","journal-title":"Cancer Lett."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Rao, S., Sengupta, R., Choe, E.J., Woerner, B.M., Jackson, E., Sun, T., Leonard, J., Piwnica-Worms, D., and Rubin, J.B. (2012). CXCL12 mediates trophic interactions between endothelial and tumor cells in glioblastoma. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033005"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"C175","DOI":"10.1152\/ajpcell.00344.2009","article-title":"CXCL12-induced glioblastoma cell migration requires intermediate conductance Ca2+-activated K+ channel activity","volume":"299","author":"Sciaccaluga","year":"2010","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"14259","DOI":"10.18632\/oncotarget.7423","article-title":"BK K+ channel blockade inhibits radiation-induced migration\/brain infiltration of glioblastoma cells","volume":"7","author":"Edalat","year":"2016","journal-title":"Oncotarget"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cell.2013.02.021","article-title":"Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth","volume":"153","author":"Cheng","year":"2013","journal-title":"Cell"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s41586-018-0389-3","article-title":"Human glioblastoma arises from subventricular zone cells with low-level driver mutations","volume":"560","author":"Lee","year":"2018","journal-title":"Nature"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Goffart, N., Lombard, A., Lallemand, F., Kroonen, J., Nassen, J., Di Valentin, E., Berendsen, S., Dedobbeleer, M., Willems, E., and Robe, P. (2016). CXCL12 mediates glioblastoma resistance to radiotherapy in the subventricular zone. Neuro-Oncology.","DOI":"10.1093\/neuonc\/now136"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4149\/neo_2017_502","article-title":"Mechanisms regulating radiosensitivity of glioma stem cells","volume":"64","author":"Liu","year":"2017","journal-title":"Neoplasma"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1158\/1078-0432.CCR-09-2329","article-title":"CXCL12 (SDF-1)\/CXCR4 pathway in cancer","volume":"16","author":"Teicher","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cyto.2018.02.020","article-title":"Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies","volume":"109","author":"Peled","year":"2018","journal-title":"Cytokine"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1080\/17460441.2016.1233176","article-title":"Drug design strategies focusing on the CXCR4\/CXCR7\/CXCL12 pathway in leukemia and lymphoma","volume":"11","author":"Barbieri","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1158\/0008-5472.465.65.2","article-title":"CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers","volume":"65","author":"Kryczek","year":"2005","journal-title":"Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.yexcr.2005.04.024","article-title":"Stromal cell-derived factor-1alpha (SDF-1alpha\/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation","volume":"308","author":"Porcile","year":"2005","journal-title":"Exp. Cell Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1096\/fj.14-260083","article-title":"SDF-1\/CXCL12 induces directional cell migration and spontaneous metastasis via a CXCR4\/Galphai\/mTORC1 axis","volume":"29","author":"Patel","year":"2015","journal-title":"FASEB J."},{"key":"ref_119","first-page":"3833","article-title":"The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases","volume":"63","author":"Zeelenberg","year":"2003","journal-title":"Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/onc.2012.37","article-title":"Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells","volume":"32","author":"Jung","year":"2013","journal-title":"Oncogene"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"10357","DOI":"10.1038\/srep10357","article-title":"Identification of a distinct population of CD133(+)CXCR4(+) cancer stem cells in ovarian cancer","volume":"5","author":"Cioffi","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1084\/jem.20052144","article-title":"A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development","volume":"203","author":"Burns","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"15735","DOI":"10.1073\/pnas.0610444104","article-title":"CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature","volume":"104","author":"Miao","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jtcvs.2012.07.031","article-title":"In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer","volume":"144","author":"Fahham","year":"2012","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1038\/sj.bjc.6605968","article-title":"CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: A novel target for therapy","volume":"103","author":"Singh","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1158\/0008-5472.CAN-12-4479","article-title":"Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer","volume":"73","author":"Ma","year":"2013","journal-title":"Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/hep.26790","article-title":"Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha\/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice","volume":"59","author":"Chen","year":"2014","journal-title":"Hepatology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jss.2008.06.044","article-title":"A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer","volume":"155","author":"Huang","year":"2009","journal-title":"J. Surg. Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1158\/0008-5472.CAN-04-1844","article-title":"CXCR4 regulates growth of both primary and metastatic breast cancer","volume":"64","author":"Smith","year":"2004","journal-title":"Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1096\/fj.03-0935fje","article-title":"Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis","volume":"18","author":"Pikarsky","year":"2004","journal-title":"FASEB J."},{"key":"ref_131","first-page":"1832","article-title":"Use of the stromal cell-derived factor-1\/CXCR4 pathway in prostate cancer metastasis to bone","volume":"62","author":"Taichman","year":"2002","journal-title":"Cancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/pros.21008","article-title":"Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth","volume":"69","author":"Porvasnik","year":"2009","journal-title":"Prostate"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1359\/JBMR.041109","article-title":"Skeletal localization and neutralization of the SDF-1(CXCL12)\/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo","volume":"20","author":"Sun","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.27665","article-title":"CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice","volume":"61","author":"Chen","year":"2015","journal-title":"Hepatology"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1078-0432.CCR-16-1730","article-title":"Plerixafor Improves Primary Tumor Response and Reduces Metastases in Cervical Cancer Treated with Radio-Chemotherapy","volume":"23","author":"Chaudary","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Thomas, R.P., Nagpal, S., Iv, M., Soltys, S.G., Bertrand, S., Pelpola, J.S., Yang, J., Ball, R.L., Brown, M., and Recht, L.D. (2018). CXCR4 blockade at the end of irradiation to improve local control of glioblastoma (GBM). J. Clin. Oncol., 36.","DOI":"10.1200\/JCO.2018.36.15_suppl.2019"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1158\/1078-0432.CCR-18-1025","article-title":"Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma","volume":"24","author":"Lee","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/leu.2017.5","article-title":"Olaptesed pegol, an anti-CXCL12\/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed\/refractory multiple myeloma: A Phase IIa Study","volume":"31","author":"Ludwig","year":"2017","journal-title":"Leukemia"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1158\/0008-5472.CAN-09-3642","article-title":"The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects","volume":"70","author":"Hattermann","year":"2010","journal-title":"Cancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.4161\/cbt.6.7.4362","article-title":"Nestin, PDGFRbeta, CXCL12 and VEGF in glioma patients: Different profiles of (pro-angiogenic) molecule expression are related with tumor grade and may provide prognostic information","volume":"6","author":"Maderna","year":"2007","journal-title":"Cancer Biol. Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/3\/272\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:34:43Z","timestamp":1760186083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/3\/272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,26]]},"references-count":141,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["cancers11030272"],"URL":"https:\/\/doi.org\/10.3390\/cancers11030272","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,26]]}}}